Project Grant HT94252510153
Award Date
4/1/25
Completion Date
3/31/29
Dollars Obligated
$1.6M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Kansas City, KS 66101, USA
Similar Awards
The University of Kansas Medical Center Research Institute, Inc. (KUMCRI) was awarded a $310,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund KUMCRI's research project "Discovery of Novel, Early Response Biomarkers for Trials in ADPKD" from September 30, 2023 to April 30, 2025.
As a not-for-profit medical research organization, KUMCRI will use this funding to conduct...
The University of Kansas Medical Center Research Institute, Inc. (KUMCRI) was awarded a $766,886.00 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) on Sep 30, 2023. The 2-year grant supports research on the importance of NKG2D signaling-induced IL-24 secretion by tumor-specific CD8+ T cells. Through this biomedical research project, KUMCRI aims to investigate medical solutions that could transform health care for Service...
This $1,395,000 Project Grant award from the Department of Defense's Defense Health Agency was made to the University of Kansas Medical Center Research Institute, Inc. (KUMCRI) on April 1, 2024. The grant is funded under the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research related to military medicine, with a focus on areas such as cancer and neurological disorders.
The purpose of this 3-year grant is to develop a short peptide-based...
This $309,928 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research at the University of Kansas Medical Center Research Institute, Inc. (KUMCRI) to investigate ferritin as a biomarker for progression of autosomal polycystic kidney disease. The 2-year project, which began on February 1, 2024, aims to advance scientific knowledge and develop innovative therapies in this area of kidney disease. KUMCRI, a...
This $1,617,200 federal Project Grant award, issued by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research program), supports research to investigate the immune microenvironments that impact HIV persistence and expression during antiretroviral therapy. The research aims to determine the location, phenotype, and microenvironment of HIV RNA-expressing cells in secondary lymphoid tissues of people with HIV on prolonged antiretroviral...
This $620,000 Project Grant, awarded on June 15, 2024 by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research by the University of Kansas Medical Center Research Institute, Inc. (KUMCRI) to elucidate the late effects of radiation in head and neck cancer patients. The research aims to advance scientific knowledge and develop innovative therapies in the field of cancer. As a prime federal grant recipient, KUMCRI has an extensive...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) totaling $2,059,030.04 supports research to develop anti-proliferative therapies to limit the HIV reservoir and potentially achieve HIV remission in non-human primate models.
The grantee, Fred Hutchinson Cancer Center, is conducting preclinical testing of small molecule agents that target CD4+ T cell proliferation, both in vitro and in vivo in...
This federal Project Grant award, valued at $645,900 and issued by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research), will support a comprehensive and prospective investigation of the extent and impact of transmitted and acquired HIV drug resistance in a large HIV care program in Kenya.
The award will enable the primary grantee, The Miriam Hospital Lifespan Division, to enroll and follow 1,840 Kenyan persons living with HIV...
This $502,861 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research on the role of the protein PCIF1 in regulating host-HIV interactions. The key objectives are to: 1) Define the dynamics and mapping of human N6,2'-O-dimethyladenosine (m6Am) RNA methylome in response to HIV infection and methamphetamine exposure; 2) Determine how HIV alters the m6Am methylome of host cells; and 3)...
This $1,421,737 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research to determine the molecular mechanism by which histone decrotonylation regulates HIV latency.
The primary objectives are to (1) investigate how histone crotonylation, distinct from acetylation, regulates HIV transcription, (2) elucidate how decrotonylation uniquely impacts HIV latency, and (3)...